Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 6, 1998, Pages 735-740

  Abate, Getahun ^a   Miörner, Håkan ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAMASE; CLAVULANIC ACID; ETHAMBUTOL; NITROCEFIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DENMARK; DRUG POTENTIATION; ETHIOPIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

AMOXICILLIN; ANTITUBERCULAR AGENTS; BETA-LACTAMASES; CLAVULANIC ACID; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0032415564     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.6.735     Document Type: Article

References (23)

1. Cohn, D. L., Bustreo, F. & Raviglione, M. C. (1997). Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clinical Infectious Diseases 24, Suppl. 1, S121-30.
2. Dolin, P. J., Raviglione, M. C. & Kochi, A. (1994). Global tuberculosis incidence and mortality during 1990-2000. Bulletin of the World Health Organization 72, 213-20.
3. Medeiros, A. A. (1997). Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clinical Infectious Diseases 24, Suppl. 1, S19-45.
4. Chambers, H. F., Moreau, D., Yajko, D., Miick, C., Wagner, C., Hackbarth, C. et al. (1995). Can penicillins and other β-lactam antibiotics be used to treat tuberculosis? Antimicrobial Agents and Chemotherapy 39, 2620-4.
5. Kasik, J. E., Monick, M. & Schwarz, B. (1980). β-Lactamase activity in slow-growing nonpigmented mycobacteria and their sensitivity to certain β-lactam antibiotics. Tubercle and Lung Disease, 61, 213-9.
6. Nash, D. R., Wallace, R. J., Steingrube. V. A., Udou, T., Steele, L. C. & Forrester, G. D. (1986). Characterization of β-lactamases in Mycobacterium fortuitum including a role in β-lactam resistance and evidence of partial inducibility. American Review of Respiratory Disease 134, 1276-82.
7. Prabhakaran, K., Harris, E. B., Randhawa, B., Adams, L. B., Williams, D. L. & Hastings, R. C. (1993). Use of β-lactam/ β-lactamase-inhibitor combinations as antimycobacterial agents. Microbios 76, 251-61.
8. Herbert, D., Paramasivan, C. N., Venkatesan, P., Kubendiran, G., Prabhakar, R. & Mitchison, D. A. (1996). Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 40, 2296-9.
9. Kwon, H. H., Tomioka, H. & Saito, H. (1995). Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tubercle and Lung Disease 76, 141-8.
10. Jarlier, V., Gutmann, L. & Nikaido, H. (1991). Interplay of cell wall barrier and β-lactamase activity determines high resistance to β-lactam antibiotics in Mycobacterium chelonae. Antimicrobial Agents and Chemotherapy 35, 1937-9.
11. Hoffner, S. E., Hjelm, U. & Källenius, G. (1993). Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrobial Agents and Chemotherapy 37, 1285-8.
12. Hoffner, S. E., Svenson, S. B. & Källenius, G. (1987). Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. European Journal of Clinical Microbiology 6, 530-5.
13. Kent, P. T. & Kubica, G. P. (1985). Public Health Mycobacteriology. A Guide for the Level III Laboratory. CDC, Atlanta.
14. Moore, T. D., Horton, R., Utrup, L. J., Miller, L. A. & Poupard, J. A. (1996). Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay. Journal of Clinical Microbiology 34, 1321-2.
15. Braga, P. C., Scaglione, F., Scarpazza, G., Fraticelli, G., Roviaro, G., Varoli, F. et al. (1985). Comparison between penetration of amoxycillin combined with carbocysteine and amoxycillin alone in pathological bronchial secretions and pulmonary tissue. International Journal of Clinical Pharmacology Research 5, 331-40.
16. Brun, Y., Forey, F., Gamondes, J. P., Tebib, A., Brune, J. & Fleurette, J. (1981). Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin. Journal of Antimicrobial Chemotherapy 8, 459-66.
17. Rastogi, N., Potar, M. C. & David, H. L. (1988). Action of antituberculous and β-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare. Annales de l'Institut Pasteur - Microbiology 139, 225-32.
18. Hoffner, S. E., Källenius, G., Beezer, A. E. & Svenson, S. B. (1989). Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex. Acta Leprologica 7, Suppl. 1, 195-9.
19. Abate, G. & Hoffner, S. E. (1997). Synergistic antimycobacterial activity between ethambutol and the β-lactam drug cefepime. Diagnostic Microbiology and Infectious Disease 28, 119-22.
20. Silve, G., Valero-Guillen, P., Quemard, A., Dupont, M. A., Daffe, M. & Laneelle, G. (1993). Ethambutol inhibition of glucose metabolism in mycobacteria: a possible target of the drug. Antimicrobial Agents and Chemotherapy 37, 1536-8.
21. Takayama, K. & Kilburn, J. O. (1989). Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrobial Agents and Chemotherapy 33, 1493-9.
22. Nadler, J. P., Berger, J., Nord, J. A., Cofsky, R. & Saxena, M. (1991). Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99, 1025-6.
23. Yew, W. W., Wong, C. F., Lee, J., Wong, P. C. & Chau, C. H. (1995). Do β-lactam-β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tubercle and Lung Disease 76, 90-2.